Skip to main content

Table 1 Participants Social Demographic and Clinical characteristics according to Electrolyte exposure

From: Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin

Characteristics Study arms P-value
NaCl + Electrolyte
n (%)
NaCl alone
n (%)
Sex
 Male 4 (8.2) 2 (4.0) 0.392
 Female 45 (91.8) 48 (96.0)
Age (years)
 30–45 18 (36.7) 7 (14.0) 0.114
 46–64 21 (42.9) 35 (70)
 >65 10 (20.4) 8 (16.0)
BMI (kg/m2)
 <18.5 6 (12.2) 5 (10.0) 0.942
 18.5–24.9 23 (46.9) 22 (44.0)
 25–29.9 13 (26.5) 14 (28.0)
  ≥ 30 7 (14.3) 9 (18.0)
Smoking status
 Yes 2 (4.1) 1 (2.0) 0.552
 No 47 (95.9) 49 (98.0)
Alcohol use
 Yes 4 (8.2) 5 (10.0) 0.753
 No 45 (91.8) 45 (90.0)
Traditional medicine use
 Yes 4 (8.2) 1 (2.0) 0.168
 No 45 (91.8) 49 (98.0)
Co-morbidity
 Yes 6 (12.2) 6 (12.0) 0.640
 No 43 (87.8) 44 (98.0)
Type of cancer
 Cervical 43 (87.8) 45 (90.0) 0.590
 Esophageal 4 (8.2) 1 (2.0)
 Oral 1 (2.0) 2 (4.0)
 Others 1 (2.0) 2 (4.0)
Chemotherapy regimen use
 Cisplatin alone 47 (95.9) 46 (92.0) 0.418
 Cisplatin contained regimen 2 (4.1) 4 (8.0)
Cisplatin dose (mg)
 50–60 25 (51) 25 (50) 0.441
 61–70 20 (40.8) 15 (30)
 71–80 2 (4.1) 7 (14)
 81–90 0 0
 >90 2 (4.1) 3 (6)